BACKGROUND: The 1996 National Cancer Institute Working Group (NCI-WG 96) guidelines classified disease in individuals who had a B-cell clone with chronic lymphocytic leukemia (CLL) immunophenotype as CLL if their absolute lymphocyte count was ≥5 × 10(9)/L. The 2008 International Workshop on CLL guidelines (IWCLL 2008) classified disease as CLL if the absolute B-cell count was ≥5 × 10(9)/L or as monoclonal B-cell lymphocytosis (MBL) if the absolute B-cell count was <5 × 10(9)/L. The objective of the current study of Olmsted County, Minnesota, was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010. METHODS: Using diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database, the authors identified all patients with newly diagnosed CLL and high-count MBL from 2000 to 2010. Age-specific and sex-specific incidence rates were determined. RESULTS: According to NCI-WG 96 criteria, there were 115 patients with CLL and 8 patients with MBL during the period studied. Using the IWCLL 2008 classification, there were 79 patients with CLL and 40 patients with MBL. Rai stage distribution (low risk, intermediate risk, and high risk) using NCI-WG 96 criteria was 60.9%, 33.9%, and 5.2%, respectively, compared with 43%, 49.4%, and 7.6%, respectively, using IWCLL 2008 criteria. The age-adjusted and sex-adjusted incidence rates (per 100,000) for CLL and MBL were 10.0 and 0.66, respectively, using NCI-WG 96 criteria versus 6.8 and 3.5, respectively, using IWCLL 2008 criteria. The median time to treatment according to NCI-WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria. CONCLUSIONS: Use of the IWCLL 2008 guidelines reduced the incidence of CLL, altered the distribution of initial Rai stage at diagnosis, and shortened the median time to treatment.
BACKGROUND: The 1996 National Cancer Institute Working Group (NCI-WG 96) guidelines classified disease in individuals who had a B-cell clone with chronic lymphocytic leukemia (CLL) immunophenotype as CLL if their absolute lymphocyte count was ≥5 × 10(9)/L. The 2008 International Workshop on CLL guidelines (IWCLL 2008) classified disease as CLL if the absolute B-cell count was ≥5 × 10(9)/L or as monoclonal B-cell lymphocytosis (MBL) if the absolute B-cell count was <5 × 10(9)/L. The objective of the current study of Olmsted County, Minnesota, was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010. METHODS: Using diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database, the authors identified all patients with newly diagnosed CLL and high-count MBL from 2000 to 2010. Age-specific and sex-specific incidence rates were determined. RESULTS: According to NCI-WG 96 criteria, there were 115 patients with CLL and 8 patients with MBL during the period studied. Using the IWCLL 2008 classification, there were 79 patients with CLL and 40 patients with MBL. Rai stage distribution (low risk, intermediate risk, and high risk) using NCI-WG 96 criteria was 60.9%, 33.9%, and 5.2%, respectively, compared with 43%, 49.4%, and 7.6%, respectively, using IWCLL 2008 criteria. The age-adjusted and sex-adjusted incidence rates (per 100,000) for CLL and MBL were 10.0 and 0.66, respectively, using NCI-WG 96 criteria versus 6.8 and 3.5, respectively, using IWCLL 2008 criteria. The median time to treatment according to NCI-WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria. CONCLUSIONS: Use of the IWCLL 2008 guidelines reduced the incidence of CLL, altered the distribution of initial Rai stage at diagnosis, and shortened the median time to treatment.
Authors: Andy C Rawstron; Fiona L Bennett; Sheila J M O'Connor; Marwan Kwok; James A L Fenton; Marieth Plummer; Ruth de Tute; Roger G Owen; Stephen J Richards; Andrew S Jack; Peter Hillmen Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Tait D Shanafelt; Neil E Kay; Tim G Call; Clive S Zent; Diane F Jelinek; Betsy LaPlant; William G Morice; Curtis A Hanson Journal: Leuk Res Date: 2008-01-07 Impact factor: 3.156
Authors: Paolo Strati; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Nelson Leung; Timothy G Call; Wei Ding; Sameer A Parikh; Neil E Kay; Tait D Shanafelt Journal: Haematologica Date: 2016-09-15 Impact factor: 9.941
Authors: Neda Alrawashdh; Joann Sweasy; Brian Erstad; Ali McBride; Daniel O Persky; Ivo Abraham Journal: Ann Hematol Date: 2021-07-19 Impact factor: 3.673
Authors: Susan L Slager; Yolanda Benavente; Aaron Blair; Roel Vermeulen; James R Cerhan; Adele Seniori Costantini; Alain Monnereau; Alexandra Nieters; Jacqueline Clavel; Timothy G Call; Marc Maynadié; Qing Lan; Christina A Clarke; Tracy Lightfoot; Aaron D Norman; Joshua N Sampson; Delphine Casabonne; Pierluigi Cocco; Silvia de Sanjosé Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Sameer A Parikh; Kari G Rabe; Neil E Kay; Timothy G Call; Wei Ding; Jose F Leis; Saad S Kenderian; Eli Muchtar; Yucai Wang; Amber B Koehler; Susan M Schwager; Connie E Lesnick; Geffen Kleinstern; Daniel Van Dyke; Curtis A Hanson; Esteban Braggio; Susan L Slager; Tait D Shanafelt Journal: Blood Date: 2021-07-15 Impact factor: 25.476
Authors: A M Hurtado; T-H Chen-Liang; B Przychodzen; C Hamedi; J Muñoz-Ballester; B Dienes; M D García-Malo; A I Antón; F de Arriba; R Teruel-Montoya; F J Ortuño; V Vicente; J P Maciejewski; A Jerez Journal: Blood Cancer J Date: 2015-08-28 Impact factor: 11.037
Authors: Maxine Je Lamb; Alexandra Smith; Daniel Painter; Eleanor Kane; Timothy Bagguley; Robert Newton; Debra Howell; Gordon Cook; Ruth de Tute; Andrew Rawstron; Russell Patmore; Eve Roman Journal: BMJ Open Date: 2021-02-22 Impact factor: 2.692